Your browser doesn't support javascript.
loading
Assessment of joint bleeding and target joints in patients with severe or moderately severe hemophilia B (factor IX ≤2%) receiving prophylaxis with rIX-FP in the PROLONG-9FP clinical trial program.
Laws, Hans-Juergen; Fukutake, Katsuyuki; Lopez-Fernandez, Maria Fernanda; Li, Yanyan; Seifert, Wilfried; Tagliaferri, Annarita.
Affiliation
  • Laws HJ; Department of Paediatric Oncology, Haematology and Clinical Immunology, Centre for Child and Adolescent Health, University of Düsseldorf, Düsseldorf, Germany.
  • Fukutake K; Department of Laboratory Medicine, Tokyo Medical University Hospital, Tokyo, Japan.
  • Lopez-Fernandez MF; Department of Blood Coagulation, Ogikubo Hospital, Tokyo, Japan.
  • Li Y; Haematology Department, Complejo Hospitalario Universitario A Coruña, A Coruña, Spain.
  • Seifert W; CSL Behring, King of Prussia, Pennsylvania, USA.
  • Tagliaferri A; CSL Behring, King of Prussia, Pennsylvania, USA.
Eur J Haematol ; 111(2): 293-299, 2023 Aug.
Article in En | MEDLINE | ID: mdl-37232041
Subject(s)
Key words
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Hemophilia B / Hemophilia A Type of study: Clinical_trials / Etiology_studies Limits: Adolescent / Adult / Child / Humans Language: En Journal: Eur J Haematol Journal subject: HEMATOLOGIA Year: 2023 Document type: Article Affiliation country: Germany
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Hemophilia B / Hemophilia A Type of study: Clinical_trials / Etiology_studies Limits: Adolescent / Adult / Child / Humans Language: En Journal: Eur J Haematol Journal subject: HEMATOLOGIA Year: 2023 Document type: Article Affiliation country: Germany